SI3297654T1 - Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39) - Google Patents

Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)

Info

Publication number
SI3297654T1
SI3297654T1 SI201631300T SI201631300T SI3297654T1 SI 3297654 T1 SI3297654 T1 SI 3297654T1 SI 201631300 T SI201631300 T SI 201631300T SI 201631300 T SI201631300 T SI 201631300T SI 3297654 T1 SI3297654 T1 SI 3297654T1
Authority
SI
Slovenia
Prior art keywords
exendin
post
treatment
bariatric hypoglycemia
bariatric
Prior art date
Application number
SI201631300T
Other languages
English (en)
Inventor
Tracey L. MCLAUGHLIN
Colleen M. Craig
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of SI3297654T1 publication Critical patent/SI3297654T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
SI201631300T 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39) SI3297654T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29
EP16800621.1A EP3297654B1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with exendin(9-39)
PCT/US2016/033837 WO2016191395A1 (en) 2015-05-22 2016-05-23 Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number Publication Date
SI3297654T1 true SI3297654T1 (sl) 2021-11-30

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201631362T SI3297653T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1
SI201631300T SI3297654T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z eksendinom(9-39)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201631362T SI3297653T1 (sl) 2015-05-22 2016-05-23 Zdravljenje postbariatrične hipoglikemije z antagonisti glp-1

Country Status (17)

Country Link
US (8) US10639354B2 (sl)
EP (4) EP3297653B1 (sl)
AU (4) AU2016267057B2 (sl)
BR (2) BR112017025000A2 (sl)
CA (2) CA3024358A1 (sl)
CL (2) CL2017002911A1 (sl)
CY (2) CY1124616T1 (sl)
DK (2) DK3297654T3 (sl)
ES (2) ES2897955T3 (sl)
HR (2) HRP20211285T1 (sl)
HU (2) HUE055728T2 (sl)
LT (2) LT3297654T (sl)
PL (2) PL3297653T3 (sl)
PT (2) PT3297653T (sl)
RS (2) RS62627B1 (sl)
SI (2) SI3297653T1 (sl)
WO (2) WO2016191395A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3456340T3 (da) 2007-01-08 2022-03-21 Univ Pennsylvania Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤
EP3743097A1 (en) * 2018-01-23 2020-12-02 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
EP3867266A4 (en) * 2018-10-15 2022-07-13 Eiger Biopharmaceuticals, Inc. AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA
US20220088144A1 (en) * 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL176007B1 (pl) 1992-06-15 1999-03-31 Scios Inc Nowe pochodne polipeptydu GLP-1
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6004297A (en) 1998-01-30 1999-12-21 Novo Nordisk A/S Injection syringe
US6469021B1 (en) 1998-12-10 2002-10-22 Agouron Pharmaceuticals, Inc. Non-peptide antagonists of GLP-1 receptor and methods of use
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
US6872700B1 (en) 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
US7638598B2 (en) 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
KR20100129799A (ko) 2004-04-15 2010-12-09 알케르메스,인코포레이티드 중합체 기재 지속적 방출 방법
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
CN105056211A (zh) 2005-08-19 2015-11-18 安米林药品有限责任公司 治疗糖尿病和降低体重的毒蜥外泌肽
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
DK3456340T3 (da) 2007-01-08 2022-03-21 Univ Pennsylvania Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
NZ589390A (en) 2008-05-05 2011-11-25 Oramed Ltd Methods and compositions for oral administration of exenatide
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
JP5622725B2 (ja) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
SI2310042T1 (sl) 2008-07-08 2013-03-29 Novartis Ag Uporaba pasireotida za zdravljenje endogene hiperinzulinemične hipoglikemije
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
CN102378632A (zh) 2009-04-03 2012-03-14 雀巢产品技术援助有限公司 对促进健康的追赶生长的改进
CN102481331B (zh) 2009-06-08 2017-09-22 阿穆尼克斯运营公司 葡萄糖调节多肽及其制备和使用方法
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2768856A4 (en) 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
CA2875983A1 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤

Also Published As

Publication number Publication date
AU2022202506A1 (en) 2022-05-12
RS62627B1 (sr) 2021-12-31
PT3297654T (pt) 2021-09-06
US20210290731A1 (en) 2021-09-23
US20240000894A1 (en) 2024-01-04
US10993991B2 (en) 2021-05-04
AU2016267052A1 (en) 2017-12-14
EP3297653B1 (en) 2021-09-15
CL2017002911A1 (es) 2018-05-25
EP3978011A1 (en) 2022-04-06
US10660937B2 (en) 2020-05-26
US10639354B2 (en) 2020-05-05
WO2016191394A1 (en) 2016-12-01
AU2016267057B2 (en) 2021-12-23
EP3297654A4 (en) 2018-04-11
PL3297654T3 (pl) 2021-12-20
AU2016267057A1 (en) 2017-12-14
CA3024353A1 (en) 2016-12-01
AU2016267052B2 (en) 2022-01-20
PL3297653T3 (pl) 2022-01-31
DK3297653T3 (da) 2021-10-18
HUE055728T2 (hu) 2021-12-28
US20230346890A1 (en) 2023-11-02
ES2897955T3 (es) 2022-03-03
US20180147261A1 (en) 2018-05-31
LT3297654T (lt) 2021-10-25
ES2887723T3 (es) 2021-12-27
CL2017002913A1 (es) 2018-06-01
US20200276271A1 (en) 2020-09-03
US11617782B2 (en) 2023-04-04
CA3024358A1 (en) 2016-12-01
US10993992B2 (en) 2021-05-04
DK3297654T3 (da) 2021-09-06
CY1124616T1 (el) 2022-07-22
US20210315974A1 (en) 2021-10-14
US20200276272A1 (en) 2020-09-03
PT3297653T (pt) 2021-10-25
EP3297653A1 (en) 2018-03-28
BR112017025000A2 (pt) 2018-08-07
HUE057301T2 (hu) 2022-05-28
RS62368B1 (sr) 2021-10-29
EP3297653A4 (en) 2018-12-26
AU2022201973A1 (en) 2022-04-14
EP3936143A1 (en) 2022-01-12
BR112017024997A2 (pt) 2018-07-31
HRP20211285T1 (hr) 2022-01-07
EP3297654B1 (en) 2021-07-07
HRP20211768T1 (hr) 2022-02-18
LT3297653T (lt) 2022-01-10
SI3297653T1 (sl) 2022-01-31
US20180117122A1 (en) 2018-05-03
EP3297654A1 (en) 2018-03-28
US11622995B2 (en) 2023-04-11
CY1125147T1 (el) 2023-03-24
WO2016191395A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
LT3297654T (lt) Hipoglikemijos, atsiradusios po bariatrinės chirurgijos, gydymas eksendinu(9-39)
SG10202100803WA (en) Endoscope with pannable camera and related method
HK1248552A1 (zh) 使用川地匹坦的治療方法
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
HK1256423A1 (zh) 纖維化治療
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
HK1232071A1 (zh) 使用 抑制劑治療 感染
GB201414366D0 (en) Blood defence
SI3139948T1 (sl) Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201503008D0 (en) Treatment
AU2015904246A0 (en) Treatment of diabetes
AU2016901862A0 (en) Treatment of diabetes
HUE048860T2 (hu) 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
GB201518349D0 (en) Treatment
GB201513922D0 (en) Treatment of hyperpigmentation
GB201515739D0 (en) Treatment
GB201514008D0 (en) Treatment
AU2015902668A0 (en) Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en) Agent for treating diabetes
GB201407396D0 (en) Confectionary treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes